Risk factors
Cullinan Therapeutics (CGEM) risk factors
Item 1A of every Cullinan Therapeutics, Inc. 10-K on file, and what changed from one year to the next. Readings are automated and can be wrong; check the filing for the exact wording.
- FY2025 10-K risk factors94 risks5 new2 dropped17 reworded
Cullinan updated its risk profile to reflect its return to smaller reporting company status and the adoption of AI regulations.
Filed Mar 10, 2026 - FY2024 10-K risk factors91 risks
Clinical development of drug candidates like CLN-619, CLN-978, and zipalertinib dominates risk exposure. Substantial financial losses, reliance on limited capital, and heavy competition shape prospects. Transitioning off emerging growth company status introduces higher compliance costs.
Filed Feb 27, 2025